To assess the potential of CD155 as a target for CAR-T cell therapy in AML, we first evaluated its surface expression on 3 AML cell lines (MOLM13, U937, and THP-1) as well as on primary AML blasts from patients with AML. Here, PVR is linked to acute myeloid leukemia.